Thread regarding New York layoffs

Cellectis Workforce Reduction Amid Strategic Shift

Cellectis is undergoing a significant business transformation, leading to potential job cuts. The company is shifting its focus from CAR T cell therapies to in vivo gene editing treatments. This strategic pivot could result in up to 70% of its global workforce being laid off. Enrollment has ceased for its CAR T programs as the company prioritizes its in vivo candidates. These changes are expected to impact employees through 2027.

https://www.biospace.com/job-trends/cellectis-could-cut-70-of-workforce-in-shift-to-in-vivo-therapies


by
| 1 view | | no replies yet | Reply
Post ID: @OP+1m7cr5k7t

There are no replies in this thread yet. Be the first to post a reply below:

Post a reply

: